Drugs


Select item(s)
Key Findings
Anti-viral activity of six drugs (arbidol, baloxavir, laninamivir, oseltamivir, peramivir, and zanamivir) against SARS-Co-V-2 was tested and among them only arbidol compound demonstrated to efficiently inhibit the virus infection in vitro.
PMID 32373347
Title The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
Author(s) nameWang X, Cao R, Zhang H, Liu J, Xu M, Hu H, Li Y, Zhao L, Li W, Sun X, Yang X, Shi Z, Deng F, Hu Z, Zhong W, Wang M.
Journal Cell Discov
Impact factor4.65
Citation count52
Date of publishing2020
No significant reduction in viral load was observed from baseline to day 15 among different treatment group patients (Lopinavir/Ritonavir, IFN-Ŗ-1a, Hydroxychloroquine, and control group ).
PMID
Title Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial
Author(s) name-
Journal
Impact factor
Citation count
Date of publishing-
Among all treatment group patients, Lopinavir/ritonavir group patients experienced more serious adverse effects (52.8% in the lopinavir/ritonavir group vs. 38.5% in the control group; 54.2% in the lopinavir/ritonavir plus IFN-Ŗ-1a group vs. 38.5% in the control group). 44.1% of patients in the Hydroxychloroquine treated group had Serious adverse effects.
PMID
Title Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial
Author(s) name-
Journal
Impact factor
Citation count
Date of publishing-
No significant improvements were observed in clinical status (in terms of WHO 7-point ordinal scale) between different treatment groups (Lopinavir/Ritonavir, IFN-Ŗ-1a, Hydroxychloroquine) and control group patients on the 15th day and 29th day.
PMID
Title Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial
Author(s) name-
Journal
Impact factor
Citation count
Date of publishing-
Computational screening of Neem compounds by molecular docking and MD-simulation studies indicates Azadirachta Indica a potential inhibitor against PLpro of SARS-CoV-2.
PMID 33041371
Title Screening of potential drug from Azadiractha Indica (Neem) extracts for SARS-CoV-2 : An insight from molecular docking and MD-simulation studies
Author(s) nameBaildya N, Khan AA, Ghosh NN, Dutta T, Chattopadhyay AP.
Journal J Mol Struct
Impact factor2.19
Citation count1
Date of publishing2021 Mar 5
Virulence protein factor Nsp1 was targeted by in silico virtual screening of ligand libraries. Molecular docking simulations of the top6 screened ligands with Nsp1 were used and the ligand-Nsp1 complexes were subjected to molecular dynamics simulations to analyze the behaviours of the ligands in a virtual cell
PMID 33612076
Title Identification of the binding interactions of some novel antiviral compounds against Nsp1 protein from SARS-CoV-2 (COVID-19) through high throughput screening.
Author(s) nameChowdhury N, Bagchi A.
Journal J Biomol Struct Dyn
Impact factor3.22
Citation count1
Date of publishing2021 Feb 22
The case study is of a 66-year-old man who experienced acute colic perforation after being treated with tocilizumab and corticosteroids for his COVID-19 diagnosis.
PMID 32402416
Title Intestinal perforation in patient with COVID-19 infection treated with tocilizumab and corticosteroids. Report of a clinical case
Author(s) nameGonz√°lvez Guardiola P, D√≠ez Ares J√Ā, Peris Tom√°s N, Sebasti√°n Tom√°s JC, Navarro Mart√≠nez S.
Journal Cir Esp
Impact factor0.36
Citation count1
Date of publishing2021 Feb
Computational screening of 84 renin inhibitors by molecular docking and MD-simulation studies indicates remikiren (Ro 425892) of HoffmannLa Roche can be repurposed against the main protease SARS-CoV-2.
PMID 33370597
Title Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study
Author(s) nameRefaey RH, El-Ashrey MK, Nissan YM.
Journal Virology
Impact factor2.819
Citation count1
Date of publishing2021 Feb
Virtual screening of 22 plant bioactive compounds from Azadirachta indica, Mangifera indica, and Moringa oleifera using molecular docking techniques and ADMET studies show top 5 compounds (kaempferol, mangiferin, myrecitin, nimbolide, and quercetin) against SARS-CoV-2 Mpro
PMID 33437230
Title In-silico analysis of the inhibition of the SARS-CoV-2 main protease by some active compounds from selected African plants
Author(s) nameUmar HI, Josiah SS, Saliu TP, Jimoh TO, Ajayi A, Danjuma JB.
Journal J Taibah Univ Med Sci
Impact factor
Citation count1
Date of publishing2021 Jan 6
Computational screening of 400 compounds from Medicines from Malaria Venture Malaria box by molecular docking and MD-simulation studies indicates three Malaria_box (MB) compounds (MB_241, MB_250,MB_266 MB) the best inhibitor against Mpro of SARS-CoV-2
PMID 33131721
Title Screening Malaria-box compounds to identify potential inhibitors against SARS-CoV-2 M pro, using molecular docking and dynamics simulation studies
Author(s) nameAhamad S, Kanipakam H, Birla S, Ali MS, Gupta D.
Journal Eur J Pharmacol
Impact factor3.24
Citation count1
Date of publishing2021 Jan 5
Computational screening of 415 phytochemicals and microbial secondary metabolites by absorption, distribution, metabolism, and excretion (ADME) pharmacokinetics and molecular docking studies indicates putaminoxin B and D, jasmonic acid and jasmonic methyl ester a potential inhibitor against the main protease of SARS-CoV-2
PMID 33069672
Title ADMET profile and virtual screening of plant and microbial natural metabolites as SARS-CoV-2 S1 glycoprotein receptor binding domain and main protease inhibitors
Author(s) namePadhi S, Masi M, Chourasia R, Rajashekar Y, Rai AK, Evidente A.
Journal Eur J Pharmacol
Impact factor3.24
Citation count2
Date of publishing2021 Jan 5
Virtual screening of 2985 FDA approved drugs using in silico methods revealed 5 potential compounds (Alvesco, troglitazone, avodart, dihydroergotoxine, and fluspirilene) against SARS-CoV-2 NSP9.
PMID 33491573
Title Exploring potential inhibitor of SARS-CoV2 replicase from FDA approved drugs using insilico drug discovery methods
Author(s) nameChandra A, Gurjar V, Ahmed MZ, Alqahtani AS, Qamar I, Singh N.
Journal J Biomol Struct Dyn
Impact factor3.22
Citation count1
Date of publishing2021 Jan 25
1.Study was based on genomic homology of SARS-CoV and SARS-CoV-2. 2.The model was utilized in a screening procedure for identifying new inhibitory molecules against SARS-CoV-2 PLpro, based on GRL0617, a confirmed inhibitor of the enzyme from SARS-CoV. 3.ZINC387735 is a recently reported inhibitor of SARS-CoV-2 PLpro and was recommended to be further investigated for their potential as suppressors of PLpro enzyme of SARS-CoV-2, and for inhibiting the virus replication.
PMID 33350309
Title In silico exploration of novel protease inhibitors against coronavirus 2019 (COVID-19)
Author(s) nameJamalan M, Barzegari E, Gholami-Borujeni F.
Journal J Proteome Res
Impact factor3.8
Citation count1
Date of publishing2021 Jan 1
Computational screening of 19 different inhibitor molecules by Molecular docking,drug-like and ADMETprediction indicates HIV protease, anti-inflammatory and antibiotic inhibitors are potential lead drug molecules against spike protein and antimalarial drugs show less binding affinity against spike protein.
PMID 33152616
Title Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus
Author(s) namePrashantha CN, Gouthami K, Lavanya L, Bhavanam S, Jakhar A, Shakthiraju RG, Suraj V, Sahana KV, Sujana HS, Guruprasad NM, Ramachandra R.
Journal J Mol Graph Model
Impact factor1.93
Citation count1
Date of publishing2021 Jan
In this study, three candidates with the potential to destabilize the SP-ACE2 complex are reported. Through molecular docking, 147 drugs were evaluated and their possible binding sites in the interface region of the SP-ACE2 complex and the SP of SARS-CoV-2 were identified.
PMID 33520633
Title In-silico drug repurposing study: Amprenavir, enalaprilat, and plerixafor, potential drugs for destabilizing the SARS-CoV-2 S-protein-angiotensin-converting enzyme 2 complex
Author(s) nameBuitrón-González I, Aguilera-Durán G, Romo-Mancillas A.
Journal Results Chem
Impact factor
Citation count1
Date of publishing2021 Jan
Ivermectin-treated group patients had a lower mortality rate compared to the control group patients. Mortality also was lower in the subgroup of Ivermectin-treated patients with severe pulmonary involvement.
PMID 33065103
Title Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study
Author(s) nameRajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ.
Journal Chest
Impact factor7.22
Citation count19
Date of publishing2021 Jan
Virtual screening of 931,17,404 compounds using molecular docking, molecular dynamics and ADME studies reveal top 11 compounds as a potential inhibitor against SARS-CoV-2 Mpro. Pubchem44326934 showed the druglike properties and could be a potent inhibitor of Mpro.
PMID 33457495
Title In silico exploration of novel protease inhibitors against coronavirus 2019 (COVID-19)
Author(s) nameAghaee E, Ghodrati M, Ghasemi JB.
Journal Inform Med Unlocked
Impact factor2.11
Citation count1
Date of publishing2021
No patients in the fluvoxamine-treated group had clinical deterioration, whereas 8.3% of patients in the placebo group showed clinical deterioration.
PMID 33180097
Title Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19
Author(s) nameLenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM.
Journal JAMA
Impact factor14.78
Citation count6
Date of publishing2020 Dec 8
Compared to the placebo group patients, the fluvoxamine-treated group patients showed less serious adverse effects.
PMID 33180097
Title Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19
Author(s) nameLenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM.
Journal JAMA
Impact factor14.78
Citation count6
Date of publishing2020 Dec 8
In silico studies by virtual screening, molecular docking and molecular dynamics techniques indicating choline can be an inhibitor for SARS-CoV-2 3CLpro protease
PMID 33041350
Title Neuroprotective immunity by essential nutrient "Choline" for the prevention of SARS CoV 2 infections: An in silico study by molecular dynamics approach
Author(s) nameChowdhury P, Pathak P.
Journal Chem Phys Lett
Impact factor1.92
Citation count1
Date of publishing2020 Dec 16
Present study was aimed to target SARS-CoV-2 S-RBD with novel bioactive compounds to retrieve potential candidates that could serve as anti-coronavirus disease 2019 drugs.
PMID 33041407
Title Promising terpenes as SARS-CoV-2 spike receptor-binding domain (RBD) attachment inhibitors to the human ACE2 receptor: Integrated computational approach
Author(s) nameMuhseen ZT, Hameed AR, Al-Hasani HMH, Tahir Ul Qamar M, Li G.
Journal J Mol Liq
Impact factor4.85
Citation count4
Date of publishing2020 Dec 15
A significant increase in Aminotransferase levels was observed in patients treated with Tocilizumab (TCZ), compared to Anakinra (ANA) treated group patients.
PMID 32843231
Title High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients
Author(s) nameIglesias-Juli√°n E, L√≥pez-Veloso M, de-la-Torre-Ferrera N, Barraza-Vengoechea JC, Delgado-L√≥pez PD, Colazo-Burlato M, Ubeira-Iglesias M, Montero-Balad√≠a M, Lorenzo-Mart√≠n A, Minguito-de-la-Iglesia J, Garc√≠a-Mu√Īoz JP, Sanllorente-Sebasti√°n R, Vicente-Gonz√°lez B, Alem√°n-Alem√°n A, Buz√≥n-Mart√≠n L.
Journal J Autoimmun
Impact factor7.32
Citation count3
Date of publishing2020 Dec
HCQ did not significantly reduce the viral load in patients. No differences in the viral load reduction between the two groups of patients were observed (HCQ and control group).
PMID 33111169
Title No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19
Author(s) nameFaíco-Filho KS, Conte DD, de Souza Luna LK, Carvalho JMA, Perosa AHS, Bellei N.
Journal Braz J Microbiol
Impact factor1.67
Citation count2
Date of publishing2020 Dec
Several common serious adverse effects were observed between two groups of patients (IFX-1 and control). In the IFX-1 group, 23 serious adverse effects occurred in 9 out of 15 patients. In the control group, 19 adverse effects occurred in 7 out of 15 patients.
PMID 33015643
Title Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Author(s) nameVlaar APJ, de Bruin S, Busch M, Timmermans SAMEG, van Zeggeren IE, Koning R, Ter Horst L, Bulle EB, van Baarle FEHP, van de Poll MCG, Kemper EM, van der Horst ICC, Schultz MJ, Horn J, Paulus F, Bos LD, Wiersinga WJ, Witzenrath M, Rueckinger S, Pilz K, Brouwer MC, Guo RF, Heunks L, van Paassen P, Riedemann NC, van de Beek D.
Journal Lancet Rheumatol
Impact factor<3years
Citation count8
Date of publishing2020 Dec
55.6% and 88.9% of patients showed positive outcomes when treated with Anakinra (ANK) and Tocilizumab (TCZ), respectively. Two patients who did not improve by TCZ drug treatment were treated successfully by ANK treatment. ANK is a potential alternative drug for treating patients who are not responding to TCZ.
PMID 32843231
Title High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients
Author(s) nameIglesias-Juli√°n E, L√≥pez-Veloso M, de-la-Torre-Ferrera N, Barraza-Vengoechea JC, Delgado-L√≥pez PD, Colazo-Burlato M, Ubeira-Iglesias M, Montero-Balad√≠a M, Lorenzo-Mart√≠n A, Minguito-de-la-Iglesia J, Garc√≠a-Mu√Īoz JP, Sanllorente-Sebasti√°n R, Vicente-Gonz√°lez B, Alem√°n-Alem√°n A, Buz√≥n-Mart√≠n L.
Journal J Autoimmun
Impact factor7.32
Citation count3
Date of publishing2020 Dec